Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Ann Rheum Dis. 2015 Nov 30;75(6):1166–1169. doi: 10.1136/annrheumdis-2015-208073

Table 3.

Treatment response among patients with PR3-AAV who received RTX vs. patients with PR3-AAV who received CYC/AZA

OR1 95% CI P-value
All patients with PR3-AAV (n = 131) 2
 CR at 6 months 2.11 1.04 – 4.30 0.04
 CR at 12 months 1.96 0.95 – 4.05 0.07
 CR at 18 months 1.44 0.68 – 3.05 0.34
Patients with PR3-AAV with relapsing disease at baseline (n = 81)3
 CR at 6 months 3.57 1.43 – 8.93 <0.01
 CR at 12 months 4.32 1.53 – 12.15 <0.01
 CR at 18 months 3.06 1.05 – 8.97 0.04
1

Comparison of RTX group versus CYC/AZA group.

2

Covariates included in the model: treatment (RTX or CYC/AZA), age, sex, and status of relapsing versus new onset disease at baseline.

3

Covariates included in the model: treatment (RTX or CYC/AZA), age, and sex.

RTX = rituximab; CYC = cyclophosphamide; AZA = azathioprine; AAV = ANCA associated vasculitis; CR = complete remission; OR = odds ratio; CI = confidence interval